Durvalumab Shifts Decades Long SOC as First FDA-Approved Immunotherapy Regimen in LS-SCLC
Suresh Senan, MRCP, FRCR, PhD, details how the FDA approval of durvalumab has changed care for patients with limited-stage small cell lung cancer.
Related Articles
Study Identifies How Ovarian Cancer Protects Itself, Paves Way for Improved Immunotherapy Approach
Eczema-linked protein helps cancer survive, suggesting potential for skin drug-based treatment.
Call-for-Papers | JACC: CardioOncology
Submission Deadline: February 15, 2025 Cardio-oncology historically has focused on the cardiotoxic effects of cancer therapies; however, as our field continues to evolve, there is…
Sasanlimab Plus BCG Could Alter Treatment Paradigm in BCG-Naive, High-Risk NMIBC
Neal Shore, MD, FACS, discusses implications of data for sasanlimab plus BCG in BCG-naive, high-risk non–muscle-invasive bladder cancer.
Tisotumab Vedotin Boosts Survival in Chinese Subpopulation With Previously Treated Cervical Cancer
Tisotumab vedotin led to improved survival vs chemotherapy in a Chinese subpopulation of previously treated cervical cancer enrolled in innovaTV 301.
Tabelecleucel BLA Receives FDA CRL in Pretreated EBV+ Post-Transplant Lymphoproliferative Disease
The FDA issued a CRL to the BLA of tabelecleucel in EBV+ PTLD following at least 1 prior line of treatment.
The Power & Reach of Social Media for Reliable Patient… : Oncology Times
An abstract is unavailable.
Transforming paediatric AML trials: from failing one-size-fits-all methods to precision oncology
Nature Reviews Clinical Oncology – Paediatric acute myeloid leukaemia (AML) highlights the challenges of drug development for rare diseases, in which limited patient numbers and…
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first…
EU/UK Approvals Sought for Nogapendekin Alfa Inbakicept Plus BCG in BCG-Unresponsive NMIBC With CIS
Nogapendekin alfa inbakicept MAAs have been submitted to the EU’s EMA and the UK’s MHRA for BCG-unresponsive non–muscle-invasive bladder cancer.
New institute musters forces against lethal skin cancer – UW Medicine | Newsroom
Media Contact: Brian Donohue – bdonohue@uw.edu, 206-543-7856 Dubbed “MC3,” the institute emerged with the restructuring of programs of patient care, training and research that straddle…
